CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 1.6×, higher than 95% of its Biotechnology peers (median 0.09×)
- FinancialsAltman Z-Score -0.9: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
399.54MUSDvs all stocks (USD)
Revenue (TTM)
69.21MUSDvs all stocks (USD)
Profit Margin
-89.55%vs Biotechnology peers
Beta
0.9670xvs all stocks
52-Week Change
77.75%vs all stocks
Market Capitalization
399.54MUSDvs all stocks (USD)
Enterprise Value
406.39MUSDvs all stocks (USD)
Forward P/E
-6.44xvs Biotechnology peers
Price to Sales (TTM)
5.54xvs Biotechnology peers
Price to Book (MRQ)
3.29xvs Biotechnology peers
Enterprise to Revenue
5.87xvs Biotechnology peers
Enterprise to EBITDA
-7.33xvs Biotechnology peers
Profit Margin
-89.55%vs Biotechnology peers
Operating Margin
-69.07%vs Biotechnology peers
Return on Assets (TTM)
-11.84%vs Biotechnology peers
Return on Equity (TTM)
-59.00%vs Biotechnology peers
Revenue (TTM)
69.21MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.75USDUpdated Jul 18, 2026Quarterly Revenue Growth
15.00%vs Biotechnology peers
Gross Profit (TTM)
69.21MUSDvs all stocks (USD)
EBITDA (TTM)
-55.45MUSDvs all stocks (USD)
Net Income (TTM)
-61.98MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-7.84MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
7.69MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
65.32MUSDFY2025 · Sep 30, 2025Operating Income
-85.35MUSDvs all stocks (USD)
Pre-tax Income
-83.55MUSDFY2025 · Sep 30, 2025Income Tax Expense
-1.66MUSDFY2025 · Sep 30, 2025Net Income
-81.89MUSDFY2025 · Sep 30, 2025EBIT
-75.87MUSDFY2025 · Sep 30, 2025EBITDA (Income Statement)
-71.32MUSDFY2025 · Sep 30, 2025Research & Development
106.74MUSDFY2025 · Sep 30, 2025Selling, General & Administrative
43.93MUSDFY2025 · Sep 30, 2025Non-operating Interest Income
9.44MUSDFY2025 · Sep 30, 2025Non-operating Interest Expense
7.68MUSDFY2025 · Sep 30, 2025EPS (Basic)
-3.84USDFY2025 · Sep 30, 2025EPS (Diluted)
-3.84USDFY2025 · Sep 30, 2025Basic Shares Outstanding
21.34MSharesFY2025 · Sep 30, 2025Diluted Shares Outstanding
21.34MSharesFY2025 · Sep 30, 2025Net Income from Continuing Operations
-81.89MUSDFY2025 · Sep 30, 2025Operating Cash Flow
-23.66MUSDFY2025 · Sep 30, 2025Free Cash Flow
-36.56MUSDFY2025 · Sep 30, 2025Cash & Cash Equivalents (End of Period)
35.66MUSDFY2025 · Sep 30, 2025Income Tax Paid
109.00KUSDFY2025 · Sep 30, 2025Interest Paid
8.79MUSDFY2025 · Sep 30, 2025Starting Profit (CF Statement)
-81.89MUSDFY2025 · Sep 30, 2025Depreciation & Amortization
4.59MUSDFY2025 · Sep 30, 2025Stock-based Compensation
18.57MUSDFY2025 · Sep 30, 2025Other Non-cash Items
-952.00KUSDFY2025 · Sep 30, 2025Change in Accounts Receivable (CF)
31.76MUSDFY2025 · Sep 30, 2025Change in Accounts Payable (CF)
-1.31MUSDFY2025 · Sep 30, 2025Change in Other Assets/Liabilities
5.58MUSDFY2025 · Sep 30, 2025Capital Expenditures
-12.90MUSDFY2025 · Sep 30, 2025Purchase of Investments
-209.63MUSDFY2025 · Sep 30, 2025Sale of Investments
262.87MUSDFY2025 · Sep 30, 2025Net Investing Cash Flow
40.35MUSDFY2025 · Sep 30, 2025Other Financing Charges
-26.76MUSDFY2025 · Sep 30, 2025Net Financing Cash Flow
-26.76MUSDFY2025 · Sep 30, 2025Shares Outstanding
29.06MSharesUpdated Jul 18, 2026Float Shares
20.06MSharesUpdated Jul 18, 2026Shares Short
2.58MSharesUpdated Jul 18, 2026Short Ratio
10.17daysvs all stocks
Short % of Shares Outstanding
10.64%vs all stocks
% Held by Insiders
4.68%vs all stocks
% Held by Institutions
92.74%vs all stocks
Total Cash (MRQ)
163.77MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.63USDUpdated Jul 18, 2026Total Debt (MRQ)
186.62MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.60xvs Biotechnology peers
Current Ratio (MRQ)
3.84xvs Biotechnology peers
Book Value per Share (MRQ)
4.01USDUpdated Jul 18, 2026Total Assets
280.73MUSDvs all stocks (USD)
Total Current Assets
204.34MUSDFY2025 · Sep 30, 2025Total Liabilities
216.01MUSDFY2025 · Sep 30, 2025Total Non-current Assets
76.40MUSDFY2025 · Sep 30, 2025Total Non-current Liabilities
167.46MUSDFY2025 · Sep 30, 2025Total Current Liabilities
48.55MUSDFY2025 · Sep 30, 2025Cash & Cash Equivalents
32.30MUSDFY2025 · Sep 30, 2025Other Short-term Investments
156.57MUSDFY2025 · Sep 30, 2025Accounts Receivable
6.88MUSDFY2025 · Sep 30, 2025Accounts Payable
1.95MUSDFY2025 · Sep 30, 2025Short-term Debt
3.15MUSDFY2025 · Sep 30, 2025Other Current Liabilities
30.71MUSDFY2025 · Sep 30, 2025Long-term Debt
54.76MUSDFY2025 · Sep 30, 2025Other Non-current Liabilities
111.39MUSDFY2025 · Sep 30, 2025Common Stock (Book)
214.00KUSDFY2025 · Sep 30, 2025Retained Earnings
-404.93MUSDFY2025 · Sep 30, 2025Total Shareholders' Equity
64.72MUSDvs all stocks (USD)
52-Week Low
6.45USDUpdated Jul 18, 202652-Week High
17.15USDUpdated Jul 18, 202652-Week Change
77.75%vs all stocks
Beta
0.9670xvs all stocks
50-Day MA
13.41USDUpdated Jul 18, 2026200-Day MA
13.23USDUpdated Jul 18, 2026Avg 10-Day Volume
189.36KSharesUpdated Jul 18, 2026Avg 30-Day Volume
234.69KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-2.60USDUpdated Jul 18, 2026Other Income / Expense
39.00KUSDFY2025 · Sep 30, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 1.6×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 1.60Industry median: 0.09Industry P95: 0.88Peers compared: 261
Structural Tensions
Significant cash reserves alongside high leverageNotable
Cash (USD): 163,774,000Total Debt (USD): 186,616,992Debt-to-Equity: 1.60
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 3.84Altman Z-Score: -0.90
Financial Health
Altman Z-Score -0.9: distress zoneCritical
Altman Z-Score: -0.90
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Abeona Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Bioeasy Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Blau Farmacêutica S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aarti Drugs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
NIOX Group plc
Tier 1ProductionApproval-Gated PipelineRule
Emergent BioSolutions Inc.
Tier 1ProductionApproval-Gated PipelineRule
Foresee Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Century Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
DiaMedica Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Kontour Xi'an Medical Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule